Abbott licenses HDC prostate cancer diagnostics

16 February 2009

USA-based Health Discovery Corp has licensed its new molecular diagnostics gene-based tests for clinically-significant prostate cancer  to health care major Abbott Laboratories.

The latter has acquired co-exclusive clinical laboratory rights and  exclusive in vitro diagnostic rights for commercialization of HDC's  tissue-based prostate cancer test as well as its urine-based prostate  cancer test.

Through the application of its patent protected technology, HDC develops  SVM-based molecular diagnostic and prognostic test development in  genomics and proteomics, as well as digital image analysis in pathology  and radiology.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight